FlowMetric Life Sciences has created and brought to market a COVID-19 antibody test. This new test delivers:
- > 99% specificity and > 99% sensitivity (> 14 days post COVID-19 symptoms)
- Ability to differentiate an infection due to virus exposure vs. a vaccine response
- Detection of antibodies over a wide dynamic range
- Simultaneous identification of antibodies to multiple SARS-CoV-2 (COVID-19) proteins
- Double the amount of information over the same testing time period vs. ELISA platform
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
"The applications of this advanced, multiplexed assay are ideal for companies working on vaccine development or COVID-19 related therapeutics," said Renold J. Capocasale, Founder and CEO of FlowMetric.
Compared with other existing antibody tests, FlowMetric's breakthrough antibody test delivers the ability to differentiate an infection due to virus exposure vs. a vaccine response, identify simultaneous detection of viral antibodies, rapid turn-around times, and excellent sensitivity and exceptional specificity on a proven, high-throughput flow cytometry platform.
The novel antibody test is offered at FlowMetric's CLIA-certified, High Complexity laboratory. FlowMetric can process over 1,000 samples per day with results provided in 24-48 hours.